Zdrowie i gospodarka · 16/11/1994

Prospective Grant of Partially Exclusive Patent License

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a partially exclusive license in a limited field of use to practice the inventions embodied in U.S. Patent 5,104,977 (formerly U.S. Patent Application 06/423,203) entitled ``Purified Transforming Growth Factor Beta'' and its foreign counterparts, including inventions deriving priority from U.S. Patent Applications 06/500,832 and 06/500,927, to Celtrix Pharmaceuticals Inc. having a place of business at Santa Clara, California. The patent rights in these inventions have been assigned to the United States of America. The prospective partially exclusive license will be for the field of ophthalmology. It will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective partially exclusive license may be granted unless, within sixty days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 40